CA2749126C - Oligomer-phenothiazine conjugates - Google Patents
Oligomer-phenothiazine conjugates Download PDFInfo
- Publication number
- CA2749126C CA2749126C CA2749126A CA2749126A CA2749126C CA 2749126 C CA2749126 C CA 2749126C CA 2749126 A CA2749126 A CA 2749126A CA 2749126 A CA2749126 A CA 2749126A CA 2749126 C CA2749126 C CA 2749126C
- Authority
- CA
- Canada
- Prior art keywords
- oligomer
- promethazine
- group
- phenothiazine
- dcm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14801609P | 2009-01-28 | 2009-01-28 | |
| US61/148,016 | 2009-01-28 | ||
| PCT/US2010/022342 WO2010088340A1 (en) | 2009-01-28 | 2010-01-28 | Oligomer-phenothiazine conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2749126A1 CA2749126A1 (en) | 2010-08-05 |
| CA2749126C true CA2749126C (en) | 2017-08-22 |
Family
ID=42101449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2749126A Active CA2749126C (en) | 2009-01-28 | 2010-01-28 | Oligomer-phenothiazine conjugates |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20120046279A1 (enExample) |
| EP (1) | EP2391386B1 (enExample) |
| JP (1) | JP5828587B2 (enExample) |
| CN (1) | CN102300588B (enExample) |
| AU (1) | AU2010208274B2 (enExample) |
| CA (1) | CA2749126C (enExample) |
| MX (1) | MX2011007940A (enExample) |
| WO (1) | WO2010088340A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008331868B2 (en) | 2007-11-28 | 2015-02-12 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
| CA2749126C (en) | 2009-01-28 | 2017-08-22 | Nektar Therapeutics | Oligomer-phenothiazine conjugates |
| WO2011091050A1 (en) * | 2010-01-19 | 2011-07-28 | Nektar Therapeutics | Oligomer-tricyclic conjugates |
| US9187439B2 (en) | 2011-09-21 | 2015-11-17 | Inception Orion, Inc. | Tricyclic compounds useful as neurogenic and neuroprotective agents |
| JP6265998B2 (ja) * | 2012-09-17 | 2018-01-24 | ネクター セラピューティクス | オリゴマー含有ベンズアミド系化合物 |
| US9695138B1 (en) * | 2016-10-17 | 2017-07-04 | Acenda Pharma, Inc. | Phenothiazine derivatives and methods of use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2530451A (en) | 1950-11-21 | Phenothiazines | ||
| US2607773A (en) | 1952-08-19 | Processes for preparing phenthi- | ||
| US2519886A (en) | 1950-08-22 | Beta-bimethylaminoethylphenothia | ||
| GB641452A (en) | 1946-12-09 | 1950-08-09 | Rhone Poulenc Sa | Improvements in or relating to the preparation of derivatives of phenthiazine |
| US3987042A (en) | 1969-03-03 | 1976-10-19 | Claude Gueremy | Phenothiazine derivative |
| FR2632521B1 (fr) | 1988-06-10 | 1990-09-14 | Rhone Poulenc Sante | Nouveaux derives de la phenothiazine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| EP1360180A1 (en) | 2001-01-19 | 2003-11-12 | Cytokinetics, Inc. | Phenothiazine kinesin inhibitors |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| WO2003002150A1 (en) | 2001-06-28 | 2003-01-09 | Wyeth | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma |
| US20050080075A1 (en) * | 2003-08-25 | 2005-04-14 | Nichols M. James | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms |
| CN1925875A (zh) * | 2003-12-16 | 2007-03-07 | 尼克塔治疗亚拉巴马公司 | 化学改性的小分子 |
| US20080112257A1 (en) * | 2006-11-10 | 2008-05-15 | Masatoshi Masuda | Mixing device for tub |
| US20100152201A1 (en) * | 2007-03-12 | 2010-06-17 | Nektar Therapeutics | Oligomer-Antihistamine Conjugates |
| CA2749126C (en) | 2009-01-28 | 2017-08-22 | Nektar Therapeutics | Oligomer-phenothiazine conjugates |
-
2010
- 2010-01-28 CA CA2749126A patent/CA2749126C/en active Active
- 2010-01-28 US US13/146,612 patent/US20120046279A1/en not_active Abandoned
- 2010-01-28 CN CN201080005673.6A patent/CN102300588B/zh active Active
- 2010-01-28 WO PCT/US2010/022342 patent/WO2010088340A1/en not_active Ceased
- 2010-01-28 EP EP10703204.7A patent/EP2391386B1/en active Active
- 2010-01-28 AU AU2010208274A patent/AU2010208274B2/en active Active
- 2010-01-28 MX MX2011007940A patent/MX2011007940A/es active IP Right Grant
- 2010-01-28 JP JP2011548281A patent/JP5828587B2/ja active Active
-
2018
- 2018-05-01 US US15/968,561 patent/US10485877B2/en active Active
-
2019
- 2019-10-11 US US16/599,605 patent/US10869933B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10485877B2 (en) | 2019-11-26 |
| US20120046279A1 (en) | 2012-02-23 |
| CN102300588B (zh) | 2014-07-16 |
| EP2391386B1 (en) | 2018-06-27 |
| JP5828587B2 (ja) | 2015-12-09 |
| JP2012516347A (ja) | 2012-07-19 |
| US20200038517A1 (en) | 2020-02-06 |
| US20180243429A1 (en) | 2018-08-30 |
| WO2010088340A1 (en) | 2010-08-05 |
| AU2010208274A1 (en) | 2011-07-21 |
| EP2391386A1 (en) | 2011-12-07 |
| CN102300588A (zh) | 2011-12-28 |
| AU2010208274B2 (en) | 2015-11-05 |
| CA2749126A1 (en) | 2010-08-05 |
| US10869933B2 (en) | 2020-12-22 |
| MX2011007940A (es) | 2011-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5827123B2 (ja) | 乱用の可能性が低いｐｅｇ化オピオイド | |
| US10869933B2 (en) | Oligomer-phenothiazine conjugates | |
| EP2121031B1 (en) | Oligomer-antihistamine conjugates | |
| US9314463B2 (en) | Oligomer-diarylpiperazine conjugates | |
| US10251959B2 (en) | Oligomer-beta blocker conjugates | |
| WO2009054916A2 (en) | Oligomer conjugates of lidocaine and its derivatives | |
| US9616136B2 (en) | N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides | |
| US9168311B2 (en) | Oligomer-dantrolene conjugates and related compounds | |
| US8389759B2 (en) | Oligomer-anticholinergic agent conjugates | |
| US20120101145A1 (en) | Oligomer-Containing Pyrrolidine Compounds | |
| EP2400989B1 (en) | Gabapentin-peg conjugates | |
| US20110009446A1 (en) | Oligomer-guanidine class conjugates | |
| US20140039020A1 (en) | Oligomer-Containing Hydantoin Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20141110 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD Year of fee payment: 15 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241210 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD Year of fee payment: 16 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251209 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251209 |